Top > Search of International Patents > CANCER TREATMENT AGENT

CANCER TREATMENT AGENT

Foreign code F190009697
File No. (P15-099(2))
Posted date Jan 23, 2019
Country WIPO
International application number 2017JP037473
International publication number WO 2018074451
Date of international filing Oct 17, 2017
Date of international publication Apr 26, 2018
Priority data
  • P2016-203793 (Oct 17, 2016) JP
  • P2017-061056 (Mar 27, 2017) JP
Title CANCER TREATMENT AGENT
Abstract The purpose of the present invention is to provide a cancer treatment agent that is characterized by combining the active ingredient caffeine citrate with an anticancer agent which is an active ingredient. Specifically provided is a cancer treatment agent having the anticancer agent cisplatin, gemcitabine, or adriamycin as an active ingredient.
Outline of related art and contending technology BACKGROUND ART
Bone sarcoma (osteosarcoma) is, in the young 10 decades primarily malignant bone tumors as a predilection for the original generation is of the most frequent, the cause is unknown.The occurrence frequency is 1 to 100 million people in Japan the rate of occurrence of a person (person 130 person 260 from the year 1) is called.In the past was the only treatment options of the amputation age, bone sarcoma and 2 - year survival rate is 15-20%, a very poor prognosis of the disease.However, the introduction of chemical therapy, and surgical therapy progress with the development of image diagnosis, the current 5 - year survival rate is greater than or equal to 70% (non-patent document 1) respectively.The inventors of the present invention, 'caffeine of the combination chemotherapy' has been disclosed.By this modality, no transition to the initial visit to complete the treatment in the example, 5 - year survival rate is 89% and is greatly improved, improving the prognosis is still insufficient, it is necessary to further improve the effect of the treatment (non-patent document 2).In addition, with regard to transition of the initial visit or any recurrence in the example, 10-30% and 5 - year survival rate is, in the past year is 40, not a significant improvement, further improvement of the effect of the treatment also in this respect is considered necessary (non-patent document 3).
Is soft (soft sarcoma) sarcoma, leiomyosarcoma, fibrosarcoma, fat sarcoma, Rhabdomyosarcoma such as the various classification.Each has different properties, a very high degree of rarity.Ewing sarcoma of the outer bone, except rhabdosarcoma in non-small circular sarcoma cells, limb development and stage III is not limited to, surgery alone is about 35% 10 - year survival rate has been reported (Non-Patent Document 4).Further, the progress of high-grade effects of chemotherapy for example soft tissue sarcoma is, has been reported in the response rate and 30-40%, compared to the soft tissue sarcoma is a bone, a disease retardment to further improving the prognosis (Non-Patent Document 5-7).The current standard of treatment methods are soft sarcoma, grade, tumor type and depending on the condition of the patient, preoperative chemotherapy and surgery and post-operative chemotherapy (wide resection) and a combination of the base.Chemical therapy, such as doxorubicin and cisplatin was used Polychemotherapeutic therapy.As described above, the treatment method, treatment effect is not necessarily satisfactory, because the height of the soft tissue sarcoma rare, the development of new drugs is a problem that does not easily occur.
As mentioned above, in various cancer types effect can be produced, conventional chemotherapy has a therapeutic effect is more robust than the new therapeutic agents has been desired.
Scope of claims (In Japanese)請求の範囲 [請求項1]
 有効成分であるカフェインクエン酸塩を、有効成分である抗癌剤と組み合わせたことを特徴とする癌治療剤。

[請求項2]
 前記癌は、原発生悪性骨腫瘍、軟部肉腫、肺癌、胃癌、乳癌、子宮癌、大腸癌、皮膚癌、卵巣癌、膵癌、胆管癌又は肝細胞癌である、請求項1に記載の癌治療剤。

[請求項3]
 前記抗癌剤が、シスプラチン、ゲムシタビン又はアドリアマイシンである請求項1又は請求項2に記載の癌治療剤。

[請求項4]
 前記癌は、骨肉腫である、請求項1~3のいずれか1に記載の癌治療剤。

[請求項5]
 前記癌は、軟部肉腫である、請求項1~3のいずれか1に記載の癌治療剤。

[請求項6]
 前記癌は、肺癌である、請求項1~3のいずれか1に記載の癌治療剤。

[請求項7]
 前記癌は、膵癌である、請求項1~3のいずれか1に記載の癌治療剤。

[請求項8]
 前記癌は、胃癌である、請求項1~3のいずれか1に記載の癌治療剤。

[請求項9]
 前記癌は、肝細胞癌である、請求項1~3のいずれか1に記載の癌治療剤。

[請求項10]
 前記癌は、子宮癌である、請求項1~3のいずれか1に記載の癌治療剤。

[請求項11]
 前記癌は、乳癌である、請求項1~3のいずれか1に記載の癌治療剤。

[請求項12]
 前記癌は、卵巣癌である、請求項1~3のいずれか1に記載の癌治療剤。

[請求項13]
 前記癌は、皮膚癌である、請求項1~3のいずれか1に記載の癌治療剤。

[請求項14]
 前記癌は、胆管癌である、請求項1~3のいずれか1に記載の癌治療剤。

[請求項15]
 有効成分であるカフェインクエン酸塩と有効成分である抗癌剤を癌患者に投与することを特徴とする癌治療方法。

[請求項16]
 前記癌患者は、原発生悪性骨腫瘍、軟部肉腫、肺癌、胃癌、乳癌、子宮癌、大腸癌、皮膚癌、卵巣癌、膵癌、胆管癌又は肝細胞癌患者である、請求項15に記載の癌治療方法。

[請求項17]
 前記抗癌剤が、シスプラチン、アドリアマイシン又はゲムシタビンである請求項15又は請求項16に記載の癌治療方法。

  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY
  • Inventor
  • TSUCHIYA,Hiroyukio
  • TAKEUCHI,Akihiko
  • ABE,Kensaku
  • YAMAMOTO,Norio
  • HAYASHI,Katsuhiro
IPC(International Patent Classification)
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close